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[a] Eric S. Dawson, [b] Jens Meiler,* [a] Alice L. Rodriguez, [b] Brian A. Chauder, [b] Brittney S. Bates, [b] Andrew S. Felts, [b] Jeffrey P. Lamb, [b] Usha N. Menon, [b] Sataywan B. Jadhav, [b] Alexander S. Kane, [b] Carrie K. Jones, [b, c] Karen J. Gregory, [b, d] Colleen M. Niswender, [b] P. Jeffrey Conn, [b] Christopher M. Olsen, [e] Danny G. Winder, [e] Kyle A. Emmitte, [a, b] and Craig W. Lindsley* [a, b] Glutamate, the major excitatory neurotransmitter, functions in the brain via activation of ligand-gated cation channels and also the eight subtypes of class C G protein-coupled metabotropic glutamate receptors (mGlus). [1] Selective allosteric modulation of mGlu 5 has been shown to have potential for treatment of a variety of neurological disorders, [2, 3] including anxiety disorders, [4, 5] Parkinson's disease, [6] [7] [8] fragile X syndrome [9] and schizophrenia. [10] [11] [12] [13] [14] The majority of mGlu 5 negative allosteric modulators (NAMs) developed to date either contain an alkyne moiety, as in compounds 1-4, or employ the alkyne topology as basis for ligand design, [15] as in compounds 5-8 ( Figure 1 ). Only recently have mGlu 5 NAM chemotypes been identified, through high-throughput screening (HTS) campaigns, that are structurally unrelated to the classical acetylenic derivatives, such as compounds 9-12 ( Figure 1) . [16] Due to the prevalence of a "molecular switch" phenomenon in 2-methyl-6-(phenylethynyl)pyridine (MPEP)-related scaffolds, our interest focused on the discovery and development of novel mGlu 5 NAM chemotypes, by both HTS and artificial neural network (ANN) virtual screens.
High-throughput screens leverage the often diverse chemical content found in collections of small molecules (10 5 -10 6 compounds) to rapidly identify a subset of molecules with the desired activity via automated plate-based experimental assays. [17] A recent PubChem search [18] returned 120 HTS assays targeting G protein-coupled receptor (GPCR) signaling that addressed targets like RGS16-G ao (AID1441, a primary screen reporting 826 active compounds out of 218,535 tested), and 5-hydroxytryptamine (serotonin) receptor subtype 1a (5-HT 1A ) (AID567, a primary screen reporting 366 actives out of 64 907 compounds tested). The hit rates (0.4-0.6 % active) in these examples are typical of HTS and highlight the frequently encountered limitation that approximately 99.5 % of the screened compounds are routinely reported as inactive towards the desired screening target. [18, 19] Theoretically, the increase of this sparse hit rate by an order of magnitude (5 % actives) would enrich the screening results and require that only 10 % of the original total amount of compounds would need to be tested in a second round to roughly double the amount of active compounds identified. A systematic method capable of producing this level of enrichment by utilizing virtual screens would significantly reduce iterative screening costs and accelerate experimental turnaround times to facilitate more rapid discovery of novel leads.
Rodriguez and co-workers recently screened approximately 160 000 small molecules to identify allosteric modulators of mGlu 5 receptor signaling. [19] The primary assay revealed 624 potential antagonists by reduction of calcium flux at an 80 % maximally effective concentration of glutamate (EC 80 ) in an experimental screening protocol designed to detect various types of mGlu 5 allosteric modulation. In confirmatory screens that employed ten-point concentration-response curves, 345 mGlu 5 antagonists were verified. [19] This experimental HTS data set formed the basis of model development for a virtual screen of the ChemDiv screening collection of over 700 000 compounds. [20] Results of that virtual screen and pharmacological characterization of a selected set of the predicted compounds are described herein. Medicinal chemistry optimization of a new chemotype and characterization of a novel tool compound is also described, including assessment of in vivo efficacy in two different behavioral assays.
Structure-activity relationships (SARs) are built on the paradigm that structurally similar compounds typically have similar biological activity. Quantitative structure-activity relationships (QSARs) connect activity to structure by fitting a mathematical function through known SAR data: f(structure) = activity. [21] Linear regression analysis is commonly used to establish QSAR models. However, this approach assumes that the biological activity can be described as a linear combination of all the structural descriptors, which is not necessarily the case. Machine learning tools like ANNs can alleviate this problem, since they employ nonlinear functions to relate input (structure) and output (activity), as described by Winkler and co-workers. [22] The QSAR models reported here are neural networks employing one hidden layer with a variable number of inputs and hidden neurons trained with simple back-propagation of errors, or resilient propagation. [23] Once this quantitative relationship is established in a model, it can be employed to predict the activity of molecules with known structure but unknown activity. Our approach for establishing QSARs from HTS experiments includes four steps: 1) a dataset connecting molecules with known SAR needs to be obtained; 2) the structures of the molecules are described in a way that remains independent from spatial orientation (to avoid the need to perform lengthy superimpositions of the molecules); 3) training of models (ANNs) through supervised back-propagation of errors is performed; and 4) final prediction of molecular bioactivity at a given target without prior knowledge of activity for the query compounds is returned. Predicted active molecules from commercially available databases [20] (e.g., ChemDiv, ChemBridge, Enamine) are then ordered and tested to validate the model's ability to enrich for compounds with mGlu 5 pharmacologic activity. Noeske and co-workers [24, 25] recently utilized virtual screens that employed a machine learning self-organizing map (SOM) approach to search for mGlu 1 NAMs, and their efforts yielded one molecule showing potency below 1 mm, and five compounds with activities between 1 mm and 15 mm in a rat mGlu 1 experimental assay. We also have recently applied an initial version of ANN-based virtual HTS to identify new mGlu 5 positive allosteric modulators (PAMs). [26] Six models with different subsets of ADRIANA descriptors (Table 1) were trained. [26] [27] [28] The ANN model trained on all 35 descriptor categories available in the ADRIANA [29] descriptor set achieved a root mean square deviation (RMSD) value of 0.209, area under the curve (AUC) value of 0.83, and a theoretical enrichment value of 18.8 for the independent data set. The descriptor subsets and model quality measures for AUC, RMSD, and enrichment are shown in Table 2 . For the first round of model optimization, the four least sensitive descriptor categories were removed leading to an RMSD value of 0.199, an AUC value of 0.87, and an enrichment value of 28.2. Removal of eight more descriptor categories led to the optimal model with 763 descriptors and to an RMSD value of 0.201, an AUC value of 0.86, and a theoretical enrichment value of 37.6. Further reduction of the number of descriptors led to slightly inferior models that were not considered for further predictions (Figure 2 ). While the RMSD and AUC values represent the general quality of the trained ANNs, these metrics mainly capture the overall utility of the models to sort potentially active from likely inactive compounds. However, the success of a model is based primarily on the experimental enrichment of active compounds (true positives) for commercial orders and experimental testing. Therefore, the theoretical enrichment measure (see Supporting Information) was weighted more heavily in our final assessment of model metrics based on its closer correlation with the final experimental ratio of correctly identified compounds with mGlu 5 activity.
The ANN model with the highest theoretical enrichment for mGlu 5 NAMs was employed to virtually screen the ChemDiv Discovery Chemistry database of 708 416 commercially available druglike compounds.
[20] At a 10 mm potency cutoff, the model predicted a set of 42 041 active small molecules. Molecules with a weight above 600 Da, topological polar surface area greater than 130 2 , a calculated Xlog P [30] value greater than 4.0, or compounds that contained labile or reactive frag- ments were removed via automated filtration. [31, 32] Further removal of molecules with a Tannimoto substructure [33] similarity value above 0.6 reduced the predicted active compounds to be ordered to 749. These compounds were tested at the Vanderbilt Institute for Chemical Biology High-Throughput Screening Center [34] to reveal a single-point concentration (change in signal amplitude of at least three standard deviations from vehicle) experimental hit rate of 12 % (88/749 compounds) that included a putative 51 NAMs, 18 PAMs and 19 agonists. Concentration-response curves (CRCs) formed of ten data points ranging from 1 nm to 30 mm confirmed the identification of 12 NAMs, 14 PAMs and one partial agonist (EC 50 /IC 50 < 30 mm; 3.6 % overall hit rate) representing an enrichment factor of 15.7 for mGlu 5 activity compared with the original mGlu 5 experimental HTS data (0.22 % original experimental hit rate). Compounds with confirmed antagonist activity (1.6 % of predicted compounds) were enriched by a factor of 7.0 with novel mGlu 5 NAM scaffolds. The optimized mGlu 5 ANN models recognized substructure patterns related nonlinearly to biological activity in chemical scaffolds that were not used in training the method and thus allowed for identification of previously unknown mGlu 5 NAMs with novel chemotypes (Figure 3) . [35] The discovery of two novel, potent mGlu 5 NAMs 13 and 14, with IC 50 values of 75 and 124 nm, respectively, possessing a previously unknown scaffold demonstrates the success of this approach.
Particularly interesting among the confirmed active compounds from the ANN virtual screen were the two potent 2-(2-benzoxazolylamino)-4-phenylpyrimidines 13 and 14, differing only in the substituent at the 5-position of the pyrimidine ring. Structurally, these compounds represent a significant departure from known mGlu 5 NAM chemotypes. Whereas analogue 13 
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contained a 5-cyano group, the corresponding group on compound 14 was an ethyl ester. Although esters are generally not suitable for use in many applications due to esterase-mediated metabolism, cyano groups are often tolerated. The scaffold was quite attractive for a medicinal chemistry optimization program as there were multiple portions of the molecule amenable to modification and SAR development. Efforts were thus focused toward that objective. Synthetic routes used to prepare the target compounds were quite straightforward (Scheme 1). In order to access the 5-cyanopyrimidine targets with the generic structure 18, two different routes that both began with b-ketonitriles 15 were employed. Many b-ketonitriles are commercially available or can easily be prepared through additions of cyanomethanide anion to simple alkyl esters. [36] In part (I) of Scheme 1, 15 was treated with N,N-dimethylformamide/dimethyl acetal (DMF/DMA) to afford intermediate 16, which was subsequently reacted with substituted guanidines 17 under basic conditions to afford 18. Alternatively, as shown in part (II) of Scheme 1, 15 could be reacted directly with 17 in the presence of triethyl orthoformate to produce 18, and this approach was generally preferred due to superior yields and fewer side reactions.
For analogues lacking a 5-cyano substituent such as 21, palladium-mediated coupling of amines 20 with 2-chloropyridine 19 were employed (part (III) of Scheme 1). Using the synthetic routes described allowed for evaluation of three distinct areas of the chemotype: the necessity of the 5-cyano substituent, the SAR at the 6-position of the pyrimidine ring (R 1 ), and the SAR around the 2-amino substituent (R 2 ). Initial SAR exploration focused on substitution at the 4-and 5-positions of the pyrimidine core, as well as on the 2-and 3-positions of the phenyl ring. The resynthesis of hit compound 13 gave potency in good agreement with that observed with the original batch (IC 50 = 89 nm). Removal of the 5-cyano substituent resulted in a dramatic loss of potency (IC 50 > 10 mm), as did the introduction of a 4-methyl substituent on the pyrimidine ring (IC 50 > 30 mm). Isosteric replacements for the 2-amino benzoxazole, such as benzothiazoles, benzimidazoles, quinolines and pyridines, also gave compounds with diminished potency at mGlu 5 (IC 50 > 30 mm). In light of such data, the decision was made to focus SAR development on analogues containing the key 5-cyano substituent on the pyrimidine core and the 2-amino benzoxazole moiety at R 2 . Further development of SAR around substitution of the phenyl ring was continued in the context of the 5-cyanopyrimidine core (Table 3 ). In order to evaluate the effect of substituents of varying electronic character, methyl, chloro, and methoxy analogues were prepared at each position (18 a-i). Both the 2-methoxyphenyl analogue (18 g) and the 4-methylphenyl analogue (18 c) had similar activities to hit compound 13. Other analogues demonstrated reduced potency relative to 13 with 3-chlorophenyl 18 e being considerably less potent. Fluorophenyl analogues were more active than their chlorophenyl comparators (compare 18 j with 18 d and 18 k with 18 f), and analogue 18 k was equipotent to 13. Several analogues with larger electron-withdrawing groups were either inactive or weak antagonists (18 l-p). The size of the substituent on the phenyl ring was key to potency as evidenced by 4-ethylphenyl analogue 18 q (compare with 18 c) and 2-ethoxyphenyl analogue 18 r (compare with 18 g). A number of disubstituted analogues were prepared (18 s-18 bb), and these compounds were generally weak antagonists. The exceptions were 4-chloro-2-fluorophenyl analogue 18 y, 4-fluoro-2-methoxy- ChemMedChem 0000, 00, 1 -9
ÝÝ These are not the final page numbers! phenyl analogue 18 z, and 4-chloro-2-methoxyphenyl analogue 18 aa, which were only slightly less potent than 13. Interestingly, analogue 18 z was less potent than both 18 g and 18 k, which was somewhat surprising. Having identified several similarly potent mGlu 5 NAMs in this manner, subsequent efforts focused on the replacement of the phenyl ring (R 1 ) altogether. A variety of 5-and 6-membered heterocycles were evaluated with limited benefit (Table 4 ). The evaluation of pyridine (18 cc and 18 dd) and thiophene (18 ee and 18 ff) isosteres revealed that these were not well tolerated, although 3-pyridyl analogue 18 dd remained moderately potent. Similarly, napthyl analogues such as 18 gg and 18 hh were only weak antagonists. Finally, introduction of a cyclohexyl group (18 ii) resulted in only an approximately threefold decrease in potency relative to 13. The tolerance for the cyclohexyl ring is a bit surprising given the sensitivity demonstrated with other analogues (such as 18 ee and 18 ff) that are much more similar in size to hit compound 13. Based on the SARs elucidated from the analogues presented thus far, it was determined that potency was substantially influenced by relatively minor changes in this portion of the chemotype. Such observations are quite common with mGlu 5 NAMs from other chemotypes and have been noted in the literature. [37] [38] [39] [40] A final effort was made to introduce substituents onto various positions of the benzoxazole ring; however, even small groups such as methyl and fluoro were not generally tolerated.
Having a number of compounds with good functional potency in hand, an evaluation of the metabolic stability of several compounds was in order. Compounds of interest were examined with regard to their stability in human and mouse liver microsomes following 15 min of incubation. [41] A general trend of greater stability in human compared to mouse liver microsomes was noted. Enhanced stability relative to 13 was observed with 4-substituted phenyl analogues 18 c, 18 i, and 18 k. [35] The nature of the 4-substituent does not appear to be a determining factor as these compounds have similar stabilities in both species. Although there was little difference between their respective metabolic profiles in microsomes, the methyl group of 18 c was still viewed as a risk for in vivo oxidative metabolism. The fluorophenyl analogue 18 k offered a convenient and equipotent alternative without such a concern.
Consideration of the SAR and the stability data in mouse liver microsomes indicated that compound 18 k would be a potentially interesting compound for evaluation in an in vivo pharmacokinetics study. Prior to initiation of that study, more detailed molecular pharmacology studies with 18 k were conducted. A radioligand binding study (Figure 4 b) measuring the ability of the compound to compete with the equilibrium of [ 3 H]-3-methoxy-5-(pyridin-2-ylethynyl)pyridine (MeOPEPy), [42] a close structural analogue of MPEP (1), confirmed the interaction of 18 k with the known mGlu 5 allosteric binding site (mGlu 5 K i = 84 AE 14 nm). We evaluated the effects of 18 k in a native system, rat cortical astrocytes, where mGlu 5 -mediated responses have previously been studied. [43, 44] Compound 18 k induced a rightward shift in the glutamate CRC and reduced the maximal effect of glutamate (Figure 4 c) , confirming activity 50 values are the average of at least three determinations.
[b] % Glu Max is the maximum response of compounds relative to the maximal glutamate response. Data are the mean of at least three determinations.
[c] CRC does not plateau. [35] ChemMedChem 0000, 00, 1 -9 2012 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim www.chemmedchem.org
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in the native system and suggesting noncompetitive inhibition of the glutamate response. It was also important to examine the effects of 18 k in multiple signaling pathways, as it has been shown that mGlu 5 allosteric modulators can have an effect through some pathways and not others. [43, 44] To this end, we determined the effects of 18 k on the ERK1/2 phosphorylation response to glutamate in HEK293 cells expressing rat mGlu 5 . We found 18 k blocked the effect of glutamate in a concentration-dependent manner (Figure 4 d) , confirming antagonist activity in the ERK pathway. Examination of the activity of compound 18 k against other mGlu receptors [35] revealed no observable activity at 10 mm against mGlu [1] [2] [3] [4] and mGlu [6] [7] [8] . Compound 18 k was also run at 10 mm in Ricerca Bioscience's LeadProfilingScreen, [45] which evaluates the test compound in radioligand binding assays for 68 primary molecular targets from classes such as GPCRs, kinases, and ion channels, including many targets relevant to central nervous system (CNS) drug discovery. In this screen, an inhibition of more than 50 % of radioligand binding was observed only in the adenosine A 3 receptor assay (73 % inhibition of binding), indicating that 18 k has a remarkably clean pharmacology profile.
Confident of the molecular pharmacology profile, a study of the exposure of 18 k following oral (p.o.) dosing in mice was conducted. [35] Unfortunately, the results revealed no exposure above detectable limits in either plasma or brain. As such, the compound was subsequently studied using intraperitoneal (i.p.) dosing (Table 5 ). Although exposure of 18 k was only moderate in plasma (AUC = 224 ng h mL À1 ), the brain exposure was quite good (AUC = 1006 ng h g À1 ) giving a brain to plasma ratio of 4:1. [46] Protein binding studies revealed that compound ÝÝ These are not the final page numbers! MED 18 k is highly bound in both mouse plasma (99.4 %) and mouse brain homogenates (99.5 %). [47] While limited free fraction represented a concern for the ability of 18 k to function in an in vivo behavior study, the brain exposure data argued for its evaluation in spite of this fact.
Ideally, evaluation of a new tool compound such as 18 k in a behavioral assay would initially take place in an assay known to be sensitive to other mGlu 5 antagonists. It has been established that mice will bury foreign objects such as glass marbles in deep bedding. [48] Furthermore, studies have shown that low doses of anxiolytic benzodiazepines inhibit this behavior. [49] Additionally, the well known mGlu 5 NAM tool compounds MPEP (1) and fenobam are effective in this model. [50] [51] [52] Marble burying is also an operationally convenient assay, making it useful in an in vivo screening paradigm. We examined compound 18 k as well as MTEP (positive control) in this assay using a 15 min pretreatment with both compounds ( Figure 5 ). Robust inhibition of marble burying with the 15 mg kg À1 dose of MTEP was observed as expected. Significant inhibition of marble burying was also observed with 18 k at the highest dose of 56.6 mg kg
À1
. Consideration of the results in the context of the pharmacokinetic study provided some insight. In mice, the average brain concentration of 18 k at 30 min was 0.41 mm, while the brain concentration at 1 h post-treatment was 0.85 mm. The marble burying assay was conducted between the 15 and 45 min time points post-dose, so the brain concentrations at these time points are relevant. If a dose linear increase in exposure is assumed, a 56.6 mg kg À1 dose should lead to brain exposures between 2.3 and 4.8 mm. It is certainly possible that the highly protein bound nature of 18 k is restricting the availability of free drug to interact with the receptor, thus necessitating relatively high brain concentrations in order to achieve efficacy. Seeking to examine compound 18 k in a behavioral model of addiction, focus turned to a relatively new model. C57Bl/6J mice readily acquired operant responding to varied visual and auditory stimuli without prior training, a phenomenon termed operant sensation seeking (OSS). [53, 54] During this assay, mice will "self-administer" visual cues consisting of flashing lights of random duration in combination with an auditory stimulus. Recent studies using low doses of the dopamine antagonist cis-flupenthixol to disrupt dopamine signaling demonstrated increased responding for OSS stimuli, similar to effects seen with cocaine self-administration. [55] Furthermore, mice lacking mGlu 5 also fail to acquire OSS despite having normal acquisition of food self-administration, [56] suggesting that OSS would represent another interesting assay for assessment of novel mGlu 5 NAMs with therapeutic potential for addiction. Since it has also been established that mGlu 5 knockout mice do not self-administer cocaine, [57] the reinforcing effects of OSS may in fact be more similar to psychostimulants than food. Recently, the results of studies with both MTEP and the first novel small-molecule mGlu 5 NAM were reported in the OSS model. [58] Gratifyingly, compound 18 k also dose dependently reduced progressive ratio responding for OSS stimuli with no significant effects observed with a food reinforcer ( Figure 6 ). [53, 54, 56, 58] Unlike the marble burying assay, here significant efficacy was observed at both the 30 and 56.6 mg kg À1 doses of 18 k. In summary, we have developed a novel mGlu 5 NAM tool compound from a completely new 4-aryl-5-cyanopyrimidine chemotype, identified through an ANN virtual screening exercise. Although SAR in this series was somewhat flat, some compounds with excellent potency were identified. Compound 18 k is a potent noncompetitive antagonist in vitro that interacts with the known allosteric bind- ing site. It is also selective for mGlu 5 over other mGlu receptors and demonstrated excellent selectivity in a large, diverse panel of other drug targets. When examined in the marble burying model of anxiety and the OSS model of addiction, compound 18 k demonstrated efficacy. Although the molecule lacks oral bioavailability in mice and is highly protein bound, these features are overcome by intraperitoneal (i.p.) dosing and the excellent brain to plasma ratio exhibited by compound 18 k. Of particular value is the demonstration that the ANN screening approach employed here can be used as a viable method for the identification of fundamentally new chemotypes. Further studies including additional in vivo profiling of compound 18 k are planned and will be reported in due course.
